Norman Coleman, Gay Crawford to receive NCCS Stovall Award for advancing patient-centered care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Norman Coleman, associate director of NCI’s Radiation Research Program and Gay Crawford, founding director of Cancer CAREpoint, were named recipients of the National Coalition for Cancer Survivorship’s Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.

Named for longtime CEO of NCCS and three-time cancer survivor Ellen Stovall, who died in 2016, the award aims to honor her memory and advocacy by annually recognizing individuals, organizations, or other entities that are innovators in improving cancer care.

Coleman has been affiliated with NCCS since working with Stovall on the NCAB/Senate Subcommittee to Evaluate the National Cancer Program in 1993. He helped form the New England Coalition for Cancer Survivorship while at Harvard. He is senior scientific advisor to the International Cancer Expert Corps, a non-government organization focusing on global disparities in cancer care.

Crawford has counseled thousands of patients and families over the past 44 years. Some of the programs she helped found include: Hospice of the Valley, the second non-profit hospice in California; Courageous Kids, an American Cancer Society program for children with cancer; the California Cancer Registry; the Colon Cancer Free Zone, advocating for colon cancer screening; and was successful in lobbying the insurance industry to pay for breast reconstructions for patients.

In 2011, she was invited to serve as the first chair of Stanford’s new South Bay Cancer Center Patient and Family Advisory Council, helping to develop the program and keep the focus on patient-focused care. In 2013, Crawford founded Cancer CAREpoint, a Silicon Valley based nonprofit organization.

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login